- Home
- TBI vs PBYI Comparison
TBI vs PBYI Comparison
Compare TBI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- PBYI
- Stock Information
- Founded
- TBI 1985
- PBYI 2010
- Country
- TBI United States
- PBYI United States
- Employees
- TBI N/A
- PBYI N/A
- Industry
- TBI Professional Services
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- PBYI Health Care
- Exchange
- TBI Nasdaq
- PBYI Nasdaq
- Market Cap
- TBI 204.9M
- PBYI 171.7M
- IPO Year
- TBI 1996
- PBYI N/A
- Fundamental
- Price
- TBI $6.65
- PBYI $3.07
- Analyst Decision
- TBI Buy
- PBYI Strong Buy
- Analyst Count
- TBI 1
- PBYI 1
- Target Price
- TBI $10.00
- PBYI $7.00
- AVG Volume (30 Days)
- TBI 196.3K
- PBYI 319.7K
- Earning Date
- TBI 08-04-2025
- PBYI 08-07-2025
- Dividend Yield
- TBI N/A
- PBYI N/A
- EPS Growth
- TBI N/A
- PBYI 143.51
- EPS
- TBI N/A
- PBYI 0.77
- Revenue
- TBI $1,534,794,000.00
- PBYI $232,709,000.00
- Revenue This Year
- TBI $0.80
- PBYI N/A
- Revenue Next Year
- TBI $6.90
- PBYI N/A
- P/E Ratio
- TBI N/A
- PBYI $3.97
- Revenue Growth
- TBI N/A
- PBYI 2.68
- 52 Week Low
- TBI $3.45
- PBYI $2.23
- 52 Week High
- TBI $12.00
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- TBI 46.23
- PBYI 33.07
- Support Level
- TBI $7.00
- PBYI $3.23
- Resistance Level
- TBI $7.51
- PBYI $3.41
- Average True Range (ATR)
- TBI 0.38
- PBYI 0.13
- MACD
- TBI -0.04
- PBYI -0.04
- Stochastic Oscillator
- TBI 35.43
- PBYI 6.67
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.